Scientists test Drug's direct impact on aggressive uterine cancer
NCT ID NCT04494113
Summary
This early study aims to understand how a drug called triapine affects a specific type of aggressive uterine cancer. Researchers will give a single dose of the drug to 12 patients just before their scheduled cancer-removal surgery. They will then compare tumor tissue samples taken before and after the drug dose to see if it changes how the cancer cells grow.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL SEROUS ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
-
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida, 33146, United States
-
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, 33442, United States
-
UM Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida, 33324, United States
-
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, 33136, United States
-
VCU Massey Comprehensive Cancer Center
Richmond, Virginia, 23298, United States
Conditions
Explore the condition pages connected to this study.